We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
TriSalus Life Sciences, Inc. (TLSI - Free Report) shares soared 6.6% in the last trading session to close at $5.49. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 10.5% gain over the past four weeks.
The recent surge in TriSalus Life Sciences Inc.'s shares can be attributed to its strong fourth quarter and full-year 2024 results, marked by 44% YoY revenue growth in the fourth quarter and 59% for the full year, driven by the TriNav Infusion System. The company reaffirmed 2025 guidance with expected sales growth of over 50%, gross margins exceeding 87%, and a path to positive EBITDA and cash flow in the second half of 2025. Investor sentiment is further supported by the commercial launch of TriNav LV, expansion through the DELIVER program, and a strong cash position bolstered by expected funding from OrbiMed.
This company is expected to post quarterly loss of $0.20 per share in its upcoming report, which represents a year-over-year change of +63%. Revenues are expected to be $9.26 million, up 43.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For TriSalus Life Sciences, Inc., the consensus EPS estimate for the quarter has been revised 2% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on TLSI going forward to see if this recent jump can turn into more strength down the road.
TriSalus Life Sciences, Inc. is part of the Zacks Medical - Products industry. Abbott (ABT - Free Report) , another stock in the same industry, closed the last trading session 0.7% lower at $123.95. ABT has returned -9.1% in the past month.
For Abbott, the consensus EPS estimate for the upcoming report has changed +0.1% over the past month to $1.07. This represents a change of +9.2% from what the company reported a year ago. Abbott currently has a Zacks Rank of #2 (Buy).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
TriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?
TriSalus Life Sciences, Inc. (TLSI - Free Report) shares soared 6.6% in the last trading session to close at $5.49. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 10.5% gain over the past four weeks.
The recent surge in TriSalus Life Sciences Inc.'s shares can be attributed to its strong fourth quarter and full-year 2024 results, marked by 44% YoY revenue growth in the fourth quarter and 59% for the full year, driven by the TriNav Infusion System. The company reaffirmed 2025 guidance with expected sales growth of over 50%, gross margins exceeding 87%, and a path to positive EBITDA and cash flow in the second half of 2025. Investor sentiment is further supported by the commercial launch of TriNav LV, expansion through the DELIVER program, and a strong cash position bolstered by expected funding from OrbiMed.
This company is expected to post quarterly loss of $0.20 per share in its upcoming report, which represents a year-over-year change of +63%. Revenues are expected to be $9.26 million, up 43.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For TriSalus Life Sciences, Inc., the consensus EPS estimate for the quarter has been revised 2% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on TLSI going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
TriSalus Life Sciences, Inc. is part of the Zacks Medical - Products industry. Abbott (ABT - Free Report) , another stock in the same industry, closed the last trading session 0.7% lower at $123.95. ABT has returned -9.1% in the past month.
For Abbott, the consensus EPS estimate for the upcoming report has changed +0.1% over the past month to $1.07. This represents a change of +9.2% from what the company reported a year ago. Abbott currently has a Zacks Rank of #2 (Buy).